Previous 10 | Next 10 |
home / stock / cmps / cmps articles
LONDON, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access t...
The U.K. Medicines and Healthcare Regulatory Agency (MHRA) has green-lighted two separate Phase 3 trials conducted by Compass Pathways (NASDAQ: CMP...
Clinical-stage psychedelics company atai Life Sciences (NASDAQ: ATAI) reported its financial results and corporate updates for the third quart...
Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans? An average of 17 veterans committed suicide per day in 2020...
DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court The U.S. Court of Appeals for the Ninth Circuit ruled against the Drug Enforc...
COMPASS Pathways plc (NASDAQ: CMPS), the London-headquartered psychedelics biotech company reported financial results for the third quarter 20...
Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted Psychedelics companies Cybin Inc. (NYSE: CYBN) and Small Pharma In...
LONDON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (NASDAQ:CMPS) ("COMPASS" or the "company"), a biotechnology company dedicated to ...
LONDON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access t...
News, Short Squeeze, Breakout and More Instantly...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...
New research has determined that psilocybin may impact the brain. Psilocybin is the primary psychoactive compound found in hallucinogenic mushrooms. When ingested, it distorts an individual’s perception of time, among other changes. Researchers have observed that in animals, psilocyb...